Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria

Abstract

Hypothesis/Introduction: The aim of this study was to assess the antihypertensive efficacy and safety of aliskiren versus ramipril or losartan in hypertensive patients with type 2 diabetes mellitus, microalbuminuria and uncontrolled hypertension, despite the use of optimal conventional antihypertensive therapy. Materials and methods: In this open-label active comparator study, 126 patients were randomly assigned to receive 24 weeks of additional therapy with aliskiren (Group A) or either losartan or ramipril (Group B), according to whether a patient was already treated with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, respectively. Results: After 24 weeks, both treatment groups experienced a significant reduction of systolic blood pressure (−11.37% and −8.47%, respectively; both p <0.001 vs. baseline) and diastolic blood pressure levels (−10.67% and −9.28%, respectively; both p <0.001 vs. baseline), with a greater reduction of mean systolic values in Group A compared with Group B (p <0.001). Furthermore, after six months microalbuminuria was significantly decreased in both treatment groups (−67.62% and −49.1%, respectively; both p <0.001), with a reduction rate in Group A significantly higher than in Group B (p<0.001). Conclusions: The addition of aliskiren to optimal conventional therapy provided a higher reduction of blood pressure and urinary albumin excretion when compared with the addition of losartan or ramipril.

Atypical presentation of Takotsubo syndrome early after pacemaker implantation

“…At home, she was taking the following drugs: olmesartan/hydrochlorothiazide, methylprednisolone (recently suspended), pantoprazole, epoetin alfa and cholecalciferol. [37][38][39][40][41][42][43][44][45][46][47] We performed an echocardiogram that showed normal kinesis and function of LV (EF 60%), left atrium dilation (21 cm 2 ), moderate mitral and mild tricuspid regurgitation (Fig. 1A).…”

Renin Inhibition with Aliskiren: A Decade of Clinical Experience

“…The addition of ALI 300 mg in the VAL/HCTZ 160/25 mg regimen in diabetic individuals showed greater BP reductions, however this did not achieve statistical significance [60]. In a recent randomized control trial by Imbalzano et al, ALI addition to optimal antihypertensive therapy showed higher BP and microalbuminuria reductions than LOS or RAM addition in patients with uncontrolled BP and DM [79]. …”

Can Aliskiren be Considered as a New Novel Drug for Hypertension?

“…DRI also showed a significant reduction in microalbuminuria as compared to CCB/ARB after a period of six months. Hence, the addition of aliskiren to regular hypertensive drugs can be highly effective in reducing the blood pressure and urinary albumin excretion [ 53 - 57 ].…”